Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do

The radiopharmaceutical market is still nascent, said Thijs Spoor, CEO of Perspective Therapeutics, which is testing an alpha-emitting isotope, Pb-212, to target cancer cells with radiation more precisely by using peptides.